H. Dosaka-akita

发表

Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis

Y. Nasuhara, M. Munakata, Toru Takahashi, 2002, Cancer.

Pneumoconiosis-related lung cancers: preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis.

H. Dosaka-akita, Y. Kawakami, M. Katabami, 2000, American journal of respiratory and critical care medicine.

p53 and Bcl‐2 expression in pneumoconiosis‐related pre‐cancerous lesions and lung cancers: Frequent and preferential p53 expression in pneumoconiotic bronchiolar dysplasias

H. Dosaka-akita, Y. Kawakami, M. Katabami, 1998, International journal of cancer.

A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.

H. Dosaka-akita, Y. Kawakami, H. Katoh, 2001, Cancer research.

Cyclin E expression, a potential prognostic marker for non-small cell lung cancers.

H. Dosaka-akita, Y. Kawakami, H. Katoh, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic Significance of p 27 KIP 1 Protein and Ki-67 Growth Fraction in Non-small Cell Lung Cancers

H. Dosaka-akita, Y. Kawakami, H. Katoh, 2000 .

Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.

H. Dosaka-akita, Y. Kawakami, H. Katoh, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Four-dimensional treatment planning and fluoroscopic real-time tumor tracking radiotherapy for moving tumor.

H. Shirato, K. Kagei, H. Dosaka-akita, 2000, International journal of radiation oncology, biology, physics.

Insertion and fixation of fiducial markers for setup and tracking of lung tumors in radiotherapy.

Koichi Yamazaki, Shinichi Shimizu, Hiroki Shirato, 2005, International journal of radiation oncology, biology, physics.

Real‐time tumor‐tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy

Koichi Yamazaki, Shinichi Shimizu, Hiroki Shirato, 2002, Cancer.

Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.

Shinichi Shimizu, Hiroki Shirato, Kazuo Miyasaka, 2003, International journal of radiation oncology, biology, physics.

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

H. Yoshiyama, A. Takaoka, Y. Ohba, 2012, Nature Immunology.

CT-guided transbronchial biopsy using an ultrathin bronchoscope with virtual bronchoscopic navigation.

Koichi Yamazaki, Kazuo Miyasaka, Yuya Onodera, 2004, Chest.

Expression of RCAS1 in human gastric carcinoma: A potential mechanism of immune escape

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2004, Cancer science.

Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool

H. Dosaka-akita, S. Kondo, H. Katoh, 2004, British Journal of Cancer.

Impact of respiratory movement on the computed tomographic images of small lung tumors in three-dimensional (3D) radiotherapy.

H Shirato, T Nishioka, K Miyasaka, 2000, International journal of radiation oncology, biology, physics.

Small cell lung cancer and other thoracic malignancies

M. Nishimura, Y. Hosomi, M. Shibuya, 2012 .

Genetic Polymorphism of CYP 2 A 6 Gene and Tobacco-induced Lung Cancer Risk in Male Smokers 1

J. Yokota, H. Dosaka-akita, T. Kamataki, 2002 .

Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice

K. Nagai, M. Nishimura, M. Kasahara, 2015, Laboratory Investigation.

A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)

M. Nishimura, H. Dosaka-akita, T. Harada, 2017, Cancer Chemotherapy and Pharmacology.

Multiplex gene‐panel testing for lung cancer patients

S. Toyooka, S. Ikeda, Y. Yatabe, 2020, Pathology international.

Predictive Biomarker Testing for Lung Cancer: Past and Future Perspectives

H. Dosaka-akita, I. Kinoshita, Y. Hatanaka, 2022, Haigan.

Microenvironment and Immunology ATM-Mediated DNA Damage Signals Mediate Immune Escape through Integrin-a v b 3 – Dependent Mechanisms

H. Yoshiyama, A. Takaoka, H. Dosaka-akita, 2011 .

Autophagy-dependent regulation of tumor metastasis by myeloid cells

H. Dosaka-akita, Y. Kawakami, H. Yagita, 2017, PloS one.

Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer

T. Oshikiri, H. Dosaka-akita, S. Kondo, 2006, Cancer Gene Therapy.

Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors

H. Dosaka-akita, H. Shimada, T. Hiwasa, 2017, Oncotarget.

A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)

S. Fuke, M. Nishimura, H. Dosaka-akita, 2020, Cancer Chemotherapy and Pharmacology.

Surgery for Small Cell Lung Cancer: A Retrospective Analysis of 243 Patients from Japanese Lung Cancer Registry in 2004

E. Miyaoka, K. Eguchi, H. Asamura, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy

Y. Matsuno, H. Dosaka-akita, I. Kinoshita, 2011, Case Reports in Oncology.

Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer

M. Nishimura, F. Tanaka, H. Uramoto, 2021, Oncoimmunology.

Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004

E. Miyaoka, H. Asamura, H. Date, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601

M. Nishimura, H. Dosaka-akita, S. Ogura, 2011, Oncology.

TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance.

B. Viollet, H. Yoshiyama, H. Dosaka-akita, 2013, Immunity.

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

H. Yoshiyama, H. Dosaka-akita, H. Yagita, 2013, Cancer Immunology, Immunotherapy.

Expression of Bim, Noxa, and Puma in non-small cell lung cancer

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2012, BMC Cancer.

Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).

M. Nishimura, H. Dosaka-akita, T. Kojima, 2021, Lung cancer.

HLA class I antigen expression is associated with a favorable prognosis in early stage non‐small cell lung cancer

M. Nishimura, H. Dosaka-akita, F. Hommura, 2007, Cancer science.

Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer

H. Dosaka-akita, Masaki Kobayashi, K. Iseki, 2020, European Journal of Clinical Pharmacology.

Increased expression of β‐catenin predicts better prognosis in nonsmall cell lung carcinomas

M. Nishimura, K. Furuuchi, T. Moriuchi, 2002 .

METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society

S. Toyooka, S. Ikeda, Y. Yatabe, 2021, Haigan.

First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)

H. Dosaka-akita, F. Hommura, T. Harada, 2021, Scientific Reports.

Altered retinoblastoma protein expression in nonsmall cell lung cancer

W. Benedict, H. Dosaka-akita, Y. Kawakami, 1997, Cancer.

RCAS1 Expression: A Potential Prognostic Marker for Adenocarcinomas of the Lung

M. Nishimura, H. Dosaka-akita, F. Hommura, 2002, Oncology.

Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer

H. Dosaka-akita, Y. Kawakami, M. Fujino, 1995, Cancer.

Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history.

H. Dosaka-akita, Y. Kawakami, M. Fujino, 1994, American journal of clinical pathology.

Prognostic significance of the expression of ras oncogene product in non‐small cell lung cancer

H. Dosaka-akita, Y. Kawakami, H. Miyamoto, 1992, Cancer.

Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer.

H. Dosaka-akita, Y. Kawakami, M. Fujino, 1995, American journal of clinical pathology.

Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.

M. Nishimura, H. Dosaka-akita, S. Ogura, 2003, Human gene therapy.

Expression of Notch 1 and Numb in small cell lung cancer

M. Nishimura, M. Munakata, F. Tanaka, 2017 .

Up‐regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis

H. Dosaka-akita, S. Kondo, T. Itoh, 2008, Cancer.

Lung adenocarcinoma presenting with enlarged and multiloculated cystic lesions over 2 years.

S. Fuke, M. Nishimura, H. Dosaka-akita, 2004, Respiratory care.

Frequent cyclin D1 expression in chromate-induced lung cancers.

S. Fukuda, H. Dosaka-akita, Y. Kawakami, 2000, Human pathology.

Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma

M. Nishimura, H. Shirato, H. Dosaka-akita, 2007, Clinical & Experimental Metastasis.

Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology

H. Dosaka-akita, Y. Hirayama, J. Sasaki, 2016, ESMO Open.

1 Tumor-infiltrating DCs suppress nucleic acid – mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB 1

Ichiro, H. Yoshiyama, A. Takaoka, 2018 .

Eighteen novel polymorphisms of the CYP2A13 gene in Japanese.

H. Yamazaki, H. Dosaka-akita, K. Kiyotani, 2003, Drug metabolism and pharmacokinetics.

High Incidence of Extracellular Matrix Metalloproteinase Inducer Expression in Non-Small Cell Lung Cancers

T. Betsuyaku, M. Nishimura, H. Dosaka-akita, 2007, Oncology.

Genetic factors in lung disease: Atopy and bronchial asthma

M. Munakata, H. Dosaka-akita, Y. Kawakami, 1997, Respirology.

Tetramer‐blocking assay for defining antigen‐specific cytotoxic T lymphocytes using peptide‐MHC tetramer

M. Nishimura, H. Ikeda, H. Dosaka-akita, 2006, Cancer science.

cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers

M. Nishimura, H. Dosaka-akita, F. Hommura, 2003 .

Prognostic significance of p27/KIP1 protein (p27) and Ki-67 growth fraction in non-small cell lung cancers (NSCLCs)

H. Dosaka-akita, Y. Kawakami, H. Katoh, 2000 .

Human papillomavirus type 18 DNA and E6-E7 mRNA are detected in squamous cell carcinoma and adenocarcinoma of the lung.

H. Dosaka-akita, Y. Kawakami, M. Fujino, 1995, British Journal of Cancer.

Small‐volume image‐guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas

M. Nishimura, R. Onimaru, H. Shirato, 2002, Cancer.

Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2008, Cancer immunity.

Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients

Y. Matsuno, H. Dosaka-akita, S. Ferrone, 2011, International journal of oncology.

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells

M. Nishimura, M. Birrer, H. Dosaka-akita, 2008, British Journal of Cancer.

Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment

H. Dosaka-akita, I. Kinoshita, T. Noguchi, 2022, AntiCancer Research.

Paraneoplastic cerebellar degeneration (PCD) associated with squamous cell carcinoma of the lung.

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2004, Internal medicine.

Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method

H. Dosaka-akita, Masaki Kobayashi, I. Kinoshita, 2022, AntiCancer Research.

Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity

H. Dosaka-akita, Masaki Kobayashi, K. Iseki, 2017, Supportive Care in Cancer.

Method for the validation of immunohistochemical staining using SCID mouse xenografts: Expression of CD40 and CD154 in human non-small cell lung cancer

H. Dosaka-akita, T. Itoh, M. Miyamoto, 2013, Oncology reports.

Cytological Characteristics of Pulmonary Pleomorphic and Giant Cell Carcinomas

T. Hirano, Y. Matsuno, Y. Tagawa, 2011, Acta Cytologica.

Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung

H. Dosaka-akita, Y. Kawakami, S. Ogura, 2000, Cancer.

Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.

J. Yokota, H. Yamazaki, H. Dosaka-akita, 2004, Carcinogenesis.

Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Jun Yokota, J. Yokota, H. Dosaka-akita, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Mediastinal Lymph Node Staging by FDG-PET in Patients with Non-Small Cell Lung Cancer: Analysis of False-Positive FDG-PET Findings

Y. Onodera, M. Nishimura, N. Tamaki, 2003, Respiration.

Expression of Fucosyltransferase 8 Is Associated with an Unfavorable Clinical Outcome in Non-Small Cell Lung Cancers

Y. Matsuno, N. Taniguchi, H. Dosaka-akita, 2015, Oncology.

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells

Hideaki Tahara, Hideo Yagita, H. Yoshiyama, 2011, Proceedings of the National Academy of Sciences.

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

M. Nishimura, H. Dosaka-akita, T. Harada, 2018, International Journal of Clinical Oncology.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2012, Lung cancer.

Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer.

H. Aburatani, M. Nishimura, Y. Matsuno, 2011, Lung cancer.

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

M. Nishimura, Y. Matsuno, H. Dosaka-akita, 2010, Cancer.

Establishment and characterization of amylase-producing lung adenocarcinoma cell line, IMEC-2.

M. Nishimura, H. Dosaka-akita, T. Itoh, 2005, Anticancer research.

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2004, Clinical Cancer Research.

Differential retinoblastoma and p16INK4A protein expression in neuroendocrine tumors of the lung

W. Benedict, P. Cagle, H. Dosaka-akita, 2000, Cancer.

Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers

H. Dosaka-akita, Y. Kawakami, H. Katoh, 1999, British Journal of Cancer.

Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome

H. Dosaka-akita, Y. Kawakami, H. Katoh, 1999, British Journal of Cancer.

Genetic factors in lung disease Part II: Lung cancer and angiotensin converting enzyme gene

M. Munakata, H. Dosaka-akita, Y. Kawakami, 1997, Respirology.

Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.

H. Dosaka-akita, Y. Kawakami, F. Hommura, 1996, Cancer research.

Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy

H. Dosaka-akita, Masaki Kobayashi, Ayako Furugen, 2022, Journal of Cancer Research and Clinical Oncology.

Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2018, Oncotarget.

Expression of Notch1 and Numb in small cell lung cancer

M. Nishimura, M. Munakata, F. Tanaka, 2017, Oncotarget.

Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis.

Y. Matsuno, H. Dosaka-akita, T. Shichinohe, 2011, Anticancer Research.

A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.

H. Dosaka-akita, Y. Kawakami, A. Murakami, 2000, Antisense & nucleic acid drug development.

Novel signaling collaboration between TGF-β and adaptor protein Crk facilitates EMT in human lung cancer

H. Dosaka-akita, M. Tsuda, I. Kinoshita, 2016, Oncotarget.

Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers.

H. Dosaka-akita, Y. Kawakami, H. Katoh, 1998, Cancer research.

Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors

Y. Matsuno, Y. Ohba, H. Dosaka-akita, 2008, BMC Cancer.

CYP2A6 gene deletion reduces susceptibility to lung cancer.

J. Yokota, H. Dosaka-akita, T. Kamataki, 1999, Biochemical and biophysical research communications.

Clinicopathologic Features and Immune Microenvironment of Non–Small‐cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

M. Nishimura, Y. Matsuno, H. Dosaka-akita, 2018, Clinical lung cancer.

A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients

E. Miyaoka, K. Kiura, H. Dosaka-akita, 2020, Cancer science.

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2006, Lung cancer.

Expression of the immunoproteasome subunit β5i in non-small cell lung carcinomas

M. Kasahara, Y. Matsuno, H. Dosaka-akita, 2020, Journal of Clinical Pathology.

Increased Apoptosis Associated with Depressed Type of Early Intestinal Gastric Cancer

M. Nishimura, H. Dosaka-akita, Y. Kawakami, 2001, Japanese journal of cancer research : Gann.

Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.

Y. Matsuno, Masato Takahashi, H. Dosaka-akita, 2021, Japanese journal of clinical oncology.

Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells.

H. Dosaka-akita, A. Yoneda, Muhammad Baghdadi, 2014, Cancer research.

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).

M. Nishimura, H. Dosaka-akita, T. Kojima, 2019, The oncologist.

Role of targeted therapy in metastatic colorectal cancer

H. Dosaka-akita, I. Kinoshita, Y. Shimizu, 2016, World journal of gastrointestinal oncology.

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2011, Oncology.

Expression of N-Acetylglucosaminyltransferase V Is Associated with Prognosis and Histology in Non-Small Cell Lung Cancers

N. Taniguchi, H. Dosaka-akita, H. Katoh, 2004, Clinical Cancer Research.

Predictive value of expression of P53, Bcl‐2 and lung resistance‐related protein for response to chemotherapy in non‐small cell lung cancers

M. Nishimura, H. Dosaka-akita, S. Ogura, 2003, Cancer science.

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

M. Nishimura, H. Dosaka-akita, S. Ogura, 2006, British Journal of Cancer.

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

M. Nishimura, M. Munakata, H. Dosaka-akita, 2007, BMC Cancer.

Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.

M. Nishimura, M. Munakata, H. Dosaka-akita, 2005, Anticancer research.

Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

M. Nishimura, M. Munakata, H. Dosaka-akita, 2006, Anticancer research.

Clinical impact of a cancer genomic profiling test using an in‐house comprehensive targeted sequencing system

H. Dosaka-akita, I. Kinoshita, I. Yabe, 2020, Cancer science.

Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck

M. Takahara, H. Dosaka-akita, A. Homma, 2020, International Journal of Clinical Oncology.

Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2017, International Journal of Clinical Oncology.

Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902

M. Nishimura, M. Munakata, H. Dosaka-akita, 2014, Cancer Chemotherapy and Pharmacology.

18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.

Nagara Tamaki, Yasushi Shimizu, Yuji Kuge, 2011, Oncology reports.

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2016, Cancer science.

Genomic testing for pancreatic cancer in clinical practice as real-world evidence.

H. Dosaka-akita, Shigeki Tanishima, I. Kinoshita, 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non–Small Cell Lung Carcinomas

Hiroyuki Aburatani, Hirotaka Ito, Masaharu Nishimura, 2005, Clinical Cancer Research.

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas

K. Akashi, T. Nakayama, H. Dosaka-akita, 2015, Cancer Immunology Research.

Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials

M. Nishimura, H. Dosaka-akita, T. Harada, 2018, Frontiers in Pharmacology.

Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy.

Koichi Yamazaki, Hiroki Shirato, Kazuo Miyasaka, 2003, International journal of radiation oncology, biology, physics.

CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers

Koichi Yamazaki, Satoshi Oizumi, Masaharu Nishimura, 2003, Cancer science.

CD133 expression: a potential prognostic marker for non-small cell lung cancers

M. Nishimura, Y. Matsuno, H. Dosaka-akita, 2014, International Journal of Clinical Oncology.

Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)

H. Dosaka-akita, T. Kurata, H. Saito, 2020, Therapeutic advances in medical oncology.

CD 133 expression : a potential prognostic marker for non-small cell lung cancers

M. Nishimura, Y. Matsuno, H. Dosaka-akita, 2012 .

Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome

H. Dosaka-akita, Masaki Kobayashi, K. Iseki, 2019, Supportive Care in Cancer.

ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms.

H. Yoshiyama, A. Takaoka, H. Dosaka-akita, 2012, Cancer research.

Inverted Papilloma of the Nasal Cavity Presenting with Massive Amounts of Squamous Metaplastic Cells in Sputum

M. Nishimura, Y. Furuta, H. Dosaka-akita, 2002, Acta Cytologica.

Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers

N. Sakuragi, H. Dosaka-akita, H. Katoh, 2002, British Journal of Cancer.

E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2005, Cancer research.

E 1 AF / PEA 3 Activates the Rho / Rho-Associated Kinase Pathway to Increase the Malignancy Potential of Non – Small-Cell Lung Cancer Cells

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2005 .

Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4

S. Horita, H. Dosaka-akita, S. Oizumi, 2014, Cancer medicine.

Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).

M. Nishimura, M. Munakata, F. Tanaka, 2015, Lung cancer.

A Rare Case of Bronchial Glomus Tumor

H. Dosaka-akita, Y. Kawakami, H. Katoh, 2001, Respiration.

Multiple Endobronchial Schwannomas Arising at the Bronchial Spur of Two Different Sites

M. Nishimura, H. Dosaka-akita, S. Ogura, 2003 .

Phase II study of carboplatin–paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024

H. Dosaka-akita, Kunihiko Kobayashi, T. Harada, 2022, International Journal of Clinical Oncology.

Expression of E1AF/PEA3, an Ets‐related transcription factor in human non‐small‐cell lung cancers: Its relevance in cell motility and invasion

M. Nishimura, H. Dosaka-akita, H. Hiroumi, 2001, International journal of cancer.

Lobe‐Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi‐Institutional Retrospective Study Using a Propensity Score Analysis

E. Miyaoka, M. Tsuboi, H. Asamura, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bcl-2 Expression in Non-Small Cell Lung Cancers: Higher Frequency of Expression in Squamous Cell Carcinomas with Earlier pT Status

H. Dosaka-akita, Y. Kawakami, M. Katabami, 1999, Oncology.

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)

S. Toyooka, S. Ikeda, C. Ishioka, 2020, Medicine.

A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).

M. Nishimura, H. Dosaka-akita, T. Kojima, 2019, Lung cancer.

A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.

M. Nishimura, H. Dosaka-akita, F. Hommura, 2013, The oncologist.

Expression of Karyopherin Alpha 2 and Karyopherin Beta 1 Correlate with Poor Prognosis in Gastric Cancer

H. Dosaka-akita, I. Kinoshita, T. Noguchi, 2022, Oncology.

Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer.

M. Nishimura, H. Dosaka-akita, M. Imura, 2004, Japanese journal of clinical oncology.

Abstract 4641: Distinctive expression of polycomb group proteins Bmi1 and EZH2 in non-small cell lung cancers and their clinical and clinicopathological significance

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2010 .

Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners

H. Dosaka-akita, M. Katabami, I. Kinoshita, 2023, PloS one.

Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer

H. Dosaka-akita, S. Konno, I. Kinoshita, 2020, Cancer Chemotherapy and Pharmacology.

Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.

Hiroki Shirato, Mototsugu Kato, Satoshi Oizumi, 2011, Lung cancer.

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail

H. Dosaka-akita, I. Kinoshita, E. Kikuchi, 2019, Cancer science.

Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.

M. Nishimura, M. Munakata, H. Dosaka-akita, 2014, Molecular and clinical oncology.

Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer.

H. Dosaka-akita, Y. Kawakami, H. Hiroumi, 1994, Cancer research.

Ki-67 labeling indices in non-small cell lung cancer: comparison between image cytometry and flow cytometry.

K. Inoue, H. Dosaka-akita, Y. Kawakami, 1997, Cytometry.

EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment

Y. Matsuno, H. Dosaka-akita, I. Kinoshita, 2022, Cancer science.

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).

H. Dosaka-akita, F. Hommura, T. Harada, 2021, Lung cancer.

Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma

H. Tsuda, Y. Matsuno, H. Dosaka-akita, 2019, Clinical Trials.

Reduction of P/Q‐type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert‐Eaton myasthenic syndrome

H. Dosaka-akita, K. Eguchi, K. Iwanaga, 2003, Annals of neurology.

Expression of N-Acetylglucosaminyltransferase V in the Development of Human Esophageal Cancers: Immunohistochemical Data from Carcinomas and Nearby Noncancerous Lesions

M. Nishimura, N. Taniguchi, H. Dosaka-akita, 2005, Oncology.

A phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations.

M. Nishimura, H. Dosaka-akita, S. Ogura, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HPV-associated lung cancers: an international pooled analysis.

F. Khuri, J. Yokota, D. Spandidos, 2014, Carcinogenesis.

A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial.

H. Dosaka-akita, T. Harada, S. Oizumi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of tumor location and respiratory function on tumor movement estimated by real-time tracking radiotherapy (RTRT) system.

Hiroki Shirato, Kazuo Miyasaka, Masaharu Nishimura, 2005, International journal of radiation oncology, biology, physics.

Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C.

M. Nishimura, H. Dosaka-akita, Y. Ishibashi, 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

Bromodomain and extraterminal domain inhibition synergizes with WEE1‐inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer

H. Dosaka-akita, S. Konno, I. Kinoshita, 2020, International journal of cancer.

Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

T. Shiga, N. Tamaki, H. Dosaka-akita, 2013, BMC Cancer.

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

H. Dosaka-akita, F. Hommura, T. Harada, 2023, Cancer medicine.

Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker

M. Nishimura, M. Munakata, F. Tanaka, 2016, OncoTarget.

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells

M. Nishimura, M. Birrer, H. Dosaka-akita, 2008, British Journal of Cancer.

Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant

M. Nishimura, M. Birrer, H. Dosaka-akita, 2008, British Journal of Cancer.

Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival

M. Nishimura, F. Tanaka, H. Uramoto, 2020, Heliyon.

Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study

T. Shiga, N. Tamaki, H. Dosaka-akita, 2018, BMJ Open.

Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers

Y. Matsuno, H. Dosaka-akita, A. Manabe, 2023, Cancer science.

Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.

M. Nishimura, H. Dosaka-akita, Y. Kawakami, 2002, Anticancer research.

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)

Shingo Matsumoto, Daisuke Kotani, Chikashi Ishioka, 2018, Cancer science.

N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers

M. Nishimura, H. Izumi, K. Kohno, 2002, British Journal of Cancer.

Histopathologic consideration of fiducial gold markers inserted for real-time tumor-tracking radiotherapy against lung cancer.

Koichi Yamazaki, Hiroki Shirato, Yasuhiro Hida, 2008, International journal of radiation oncology, biology, physics.

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

M. Nishimura, H. Dosaka-akita, T. Harada, 2018, International Journal of Clinical Oncology.

Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers.

H. Dosaka-akita, F. Hommura, I. Kinoshita, 1998, Cancer research.

TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance.

B. Viollet, H. Yoshiyama, H. Dosaka-akita, 2013, Immunity.

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas

K. Akashi, T. Nakayama, H. Dosaka-akita, 2015, Cancer Immunology Research.

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

M. Nishimura, H. Dosaka-akita, S. Ogura, 2006, British Journal of Cancer.

A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)

M. Nishimura, H. Dosaka-akita, T. Harada, 2017, Cancer Chemotherapy and Pharmacology.

Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis.

Y. Matsuno, H. Dosaka-akita, T. Shichinohe, 2011, Anticancer research.

Feasibility study of real-time tumor-tracking radiotherapy system for lung tumors

M. Nishimura, R. Onimaru, H. Shirato, 2003 .

Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

H. Dosaka-akita, K. Hirata, Keiichi Magota, 2023, EJNMMI Research.

Polymorphisms of the PD‐L1 gene 3′‐untranslated region are associated with the expression of PD‐L1 in non‐small cell lung cancer

H. Dosaka-akita, U. Tomaru, Y. Ohhara, 2023, Genes, chromosomes & cancer.

Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas.

M. Nishimura, K. Furuuchi, T. Moriuchi, 2002, Cancer.

in a

M. Nishimura, H. Dosaka-akita, K. Yamazaki, 2023 .

Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases

H. Dosaka-akita, H. Kamachi, T. Kamiyama, 2021, International Cancer Conference Journal.

Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells.

H. Dosaka-akita, A. Yoneda, Muhammad Baghdadi, 2014, Cancer research.